100% User Fees For US FDA? Trump Budget Revives Important Issue For Industry – But Not This Year
Trump Administration’s surprising call for increased user fees probably won’t have much impact on pending reauthorization process, but it does put on the table an important question for the biopharma industry to consider for the long term: should FDA be fully funded by user fees?
You may also be interested in...
Did the head of the Office and Management & Budget really endorse Part D rebates? Like so much about the Trump Administration’s response to drug pricing, there is probably a lot less to the story than it sounds.
Cowen's Washington Strategist Chris Krueger discusses US health reform, drug pricing legislation and user fees in new podcast.
Final assessment of the PDUFA V new drug review 'Program' flagged inspection delays as a continued sticking point for on-time approvals. US FDA says consolidation of manufacturing oversight under the agency’s new quality office will help.